{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:41:07Z","timestamp":1754487667289,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00403-020-02044-7","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T09:03:49Z","timestamp":1582103029000},"page":"581-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration"],"prefix":"10.1007","volume":"312","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"issue":"20","key":"2044_CR1","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMcp0804878","volume":"360","author":"D de Berker","year":"2009","unstructured":"de Berker D (2009) Clinical practice. Fungal nail disease. N Engl J Med 360(20):2108\u20132116","journal-title":"N Engl J Med"},{"issue":"4","key":"2044_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","volume":"80","author":"SR Lipner","year":"2019","unstructured":"Lipner SR, Scher RK (2019) Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol 80(4):853\u2013867","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2044_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","volume":"80","author":"SR Lipner","year":"2019","unstructured":"Lipner SR, Scher RK (2019) Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol 80(4):835\u2013851","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"2044_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/0190-9622(95)91454-4","volume":"32","author":"J Faergemann","year":"1995","unstructured":"Faergemann J et al (1995) Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 32(5 Pt 1):750\u2013753","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2044_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0190-9622(95)90187-6","volume":"32","author":"E Haneke","year":"1995","unstructured":"Haneke E et al (1995) Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol 32(1):72\u201377","journal-title":"J Am Acad Dermatol"},{"doi-asserted-by":"crossref","unstructured":"Hofmann H et al. (1995) Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol 131(8): 919\u2013922.","key":"2044_CR6","DOI":"10.1001\/archderm.1995.01690200057011"},{"issue":"10","key":"2044_CR7","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1128\/AAC.37.10.2064","volume":"37","author":"HC Korting","year":"1993","unstructured":"Korting HC et al (1993) Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 37(10):2064\u20132068","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2044_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/0001555570137140","volume":"70","author":"I Walsoe","year":"1990","unstructured":"Walsoe I, Stangerup M, Svejgaard E (1990) Itraconazole in onychomycosis. Open and double-blind studies. Acta Derm Venereol 70(2):137\u2013140","journal-title":"Acta Derm Venereol"},{"unstructured":"Food and Drug Administration Penlac Nail Lacquer Tropical Solution. FDA approval information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21-022_Penlac.cfm. Accessed 02 Oct 2019.","key":"2044_CR9"},{"unstructured":"Food and Drug Administration Jublia topical solution (efinaconazole). FDA approval information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/203567_jublia_toc.cfm. Accessed 02 Oct 2019.","key":"2044_CR10"},{"unstructured":"Food and Drug Administration Kerydin. FDA approval information. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=204427 Accessed 02 Oct 2019.","key":"2044_CR11"},{"unstructured":"Federal Drug Administration (2019) Federal Drug Administration adverse event reporting system [database]. https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/33a0f68e-845c-48e2-bc81-8141c6aaf772\/state\/analysis.","key":"2044_CR12"},{"unstructured":"Google (2019) Google Trend [database]. https:\/\/trends.google.com\/trends\/?geo=US.","key":"2044_CR13"},{"unstructured":"Penlac nail lacquer (ciclopirox) topical solution, 8% [package insert]. Bridgewater, NJ: Dermik Laboratories. https:\/\/products.sanofi.us\/penlac\/penlac.html. Accessed 25 Sep 2019.","key":"2044_CR14"},{"unstructured":"Jubilia (efinaconazole) topical solution, 10% [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals. https:\/\/www.valeant.com\/Portals\/25\/Pdf\/PI\/Jublia-PI.pdf. Accessed 25 Sep 2018.","key":"2044_CR15"},{"unstructured":"Kerydin (tavaborole) topical solution, 5% [package insert]. Melville, NY: Fougera Pharmaceuticals. https:\/\/dailymed-nlm-nih-gov.proxy.library.stonybrook.edu\/dailymed\/drugInfo.cfm?setid=1ae61072-bca0-43f0-a741-07bda2d50c87. Accessed 27 Sep 2019.","key":"2044_CR16"},{"unstructured":"Lamisil (terbinafine hydrochloride) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/Lamisil_tablets.pdf. Accessed 25 Sep 2019.","key":"2044_CR17"},{"unstructured":"Food and Drug Administration Lamisil. FDA approval information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020749_lamisil_toc.cfm. Accessed 02 Oct 2019.","key":"2044_CR18"},{"issue":"7","key":"2044_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamadermatol.2016.0785","volume":"152","author":"SR Lipner","year":"2016","unstructured":"Lipner SR, Scher RK (2016) Confirmatory testing for onychomycosis. JAMA Dermatol 152(7):847","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2044_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1185\/03007995.2016.1147026","volume":"32","author":"SR Lipner","year":"2016","unstructured":"Lipner SR, Scher RK (2016) Onychomycosis\u2014a small step for quality of care. Curr Med Res Opin 32(5):865\u2013867","journal-title":"Curr Med Res Opin"},{"unstructured":"ClinicalTrials.gov. (2019) Efficacy and safety of AN2690 topical solution to treat onychomycosis of the toenail. https:\/\/clinicaltrials.gov\/tavaborole. Accessed 1 Nov 2019","key":"2044_CR21"},{"unstructured":"ClinicalTrials.gov. (2019) An evaluation of the safety and pharmacokinetics of tavaborole topical solution for the treatment of fungal disease of the toenail in children and adolescents. https:\/\/clinicaltrials.gov\/tavaborole. Accessed 01 Nov 2019","key":"2044_CR22"},{"unstructured":"ClinicalTrials.gov. (2019) Efficacy and safety evaluation of AN2690 topical solution to treat onychomycosis of the toenail. https:\/\/clinicaltrials.gov\/tavaborole. Accessed 01 Nov 2019","key":"2044_CR23"},{"unstructured":"ClinicalTrials.gov. (2019) Safety and efficacy study of subjects with onychomycosis of the great toenail. https:\/\/clinicaltrials.gov\/tavaborole. Accessed 01 Nov 2019","key":"2044_CR24"},{"unstructured":"Lee K (2002). Drug advertising skyrockets. https:\/\/www.cbsnews.com\/news\/drug-advertising-skyrockets\/.","key":"2044_CR25"},{"unstructured":"Sinclair N (2016). Tv Ad revenue rising pharmaceuticals drugs. https:\/\/finance.yahoo.com\/news\/tv-ad-revenue-rising-pharmaceuticals-drugs-175632922.html.","key":"2044_CR26"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-020-02044-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-020-02044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T04:09:36Z","timestamp":1695787776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-020-02044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s00403-020-02044-7","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"type":"print","value":"0340-3696"},{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yu Wang and Dr. Lipner have no conflicts of interest relevant to the content of the submission. This work has not been previously published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}